🇺🇸 FDA
Patent

US 12104172

Processes for generating TIL products enriched for tumor antigen-specific t-cells

granted A61KA61K2239/57A61K35/17

Quick answer

US patent 12104172 (Processes for generating TIL products enriched for tumor antigen-specific t-cells) held by Iovance Biotherapeutics, Inc. expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Iovance Biotherapeutics, Inc.
Grant date
Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2239/57, A61K35/17, A61K40/11, A61K40/428